Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...

FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a ...

LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, ...

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

Leerink Partnrs lifted their FY2028 EPS estimates for LENZ Therapeutics in a research report issued on Tuesday, October 15th.

LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.

Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

She most recently served as President and CEO of Graphite Bio, which she successfully merged with LENZ Therapeutics (Nasdaq: LENZ). "As we advance our development candidates for Rett syndrome and ...

On Friday, Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $16.49 which represents a decrease of $-0.47 or -2.77% from the prior close of $16.96. The stock opened at $17 and ...